MoonLake Immunotherapeutics (NASDAQ:MLTX) Coverage Initiated by Analysts at Rothschild & Co Redburn

Key Points

• Rothschild & Co Redburn has initiated coverage on MoonLake Immunotherapeutics (NASDAQ:MLTX) with a "neutral" rating and a price target of $65.00, indicating an upside potential of 18.03% from its last closing price.
• Other analysts, including Wedbush and Royal Bank of Canada, have issued "outperform" ratings with price targets ranging from $61.00 to $80.00, contributing to a consensus rating of "Moderate Buy" and an average target of $73.14.
• MoonLake reported a quarterly loss of ($0.63) EPS, which beat analysts' expectations, and has a market capitalization of $3.53 billion with significant institutional ownership of 93.85%.

Rothschild & Co Redburn started coverage on shares of MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) in a report issued on Monday morning, Marketbeat.com reports. The firm issued a neutral rating and a $65.00 target price on the stock.

MLTX has been the subject of a number of other research reports. Wedbush reissued an "outperform" rating and set a $80.00 target price (up previously from $78.00) on shares of MoonLake Immunotherapeutics in a report on Tuesday, May 13th. Royal Bank Of Canada restated an "outperform" rating and issued a $67.00 price target on shares of MoonLake Immunotherapeutics in a research report on Tuesday, June 3rd. Needham & Company LLC restated a "buy" rating and issued a $66.00 price target on shares of MoonLake Immunotherapeutics in a research report on Tuesday, May 13th. Finally, Wolfe Research upgraded MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 price target on the stock in a research report on Monday, May 19th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $73.14.

MoonLake Immunotherapeutics Stock Performance

MLTX stock traded down $0.11 during trading hours on Monday, reaching $50.36. The stock had a trading volume of 587,140 shares, compared to its average volume of 481,100. MoonLake Immunotherapeutics has a fifty-two week low of $31.42 and a fifty-two week high of $58.26. The stock has a market capitalization of $3.22 billion, a PE ratio of -21.95 and a beta of 1.27. The stock has a 50-day simple moving average of $46.95 and a 200 day simple moving average of $42.77. The company has a debt-to-equity ratio of 0.18, a current ratio of 21.11 and a quick ratio of 21.11.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last announced its earnings results on Monday, May 12th. The company reported ($0.63) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.13. During the same quarter in the prior year, the company posted ($0.22) EPS. Analysts predict that MoonLake Immunotherapeutics will post -1.79 EPS for the current fiscal year.

Hedge Funds Weigh In On MoonLake Immunotherapeutics

A number of institutional investors have recently modified their holdings of MLTX. Deutsche Bank AG boosted its position in MoonLake Immunotherapeutics by 59.8% in the fourth quarter. Deutsche Bank AG now owns 903 shares of the company's stock valued at $49,000 after buying an additional 338 shares in the last quarter. US Bancorp DE boosted its position in MoonLake Immunotherapeutics by 114.4% in the first quarter. US Bancorp DE now owns 2,208 shares of the company's stock valued at $86,000 after buying an additional 1,178 shares in the last quarter. Quarry LP acquired a new stake in shares of MoonLake Immunotherapeutics during the 1st quarter valued at $94,000. Birchview Capital LP acquired a new stake in shares of MoonLake Immunotherapeutics during the 4th quarter valued at $217,000. Finally, Advisors Asset Management Inc. boosted its holdings in shares of MoonLake Immunotherapeutics by 81.7% during the 1st quarter. Advisors Asset Management Inc. now owns 4,009 shares of the company's stock valued at $157,000 after acquiring an additional 1,803 shares in the last quarter. Institutional investors and hedge funds own 93.85% of the company's stock.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.